# The weight loss drug maker reported first quarter sales of $15.17 billion (96.82 billion Danish kroner), beating the consensus of $11.13 billion.

*business · news · 2026-05-06 · Benzinga*

## Key points

- Novo Nordisk first quarter sales reached $15.17 billion, significantly beating expectations of $11.13 billion.
- A reversal of 340B Drug Pricing Program provisions in the U.S. boosted both sales and reported profit.
- Wegovy pill prescriptions surpassed 200,000 weekly and totaled over 2 million since January launch.
- Novo Nordisk raised its 2026 sales guidance to $42.39 billion-$46.24 billion, above previous forecasts.
- Adjusted 2026 operating profit is now projected to decline 4%-12% at CER, excluding 340B provision impact.

**Companies:** Novo Nordisk
**Countries:** United States, Denmark

[Read the full story on Benzinga](https://www.benzinga.com/markets/earnings/26/05/52317144/wegovy-pill-debut-fattens-novo-nordisks-profit-outlook)

---

Canonical: https://newsio.io/n/dc59ae65-0ced-4bb0-b0b7-c99b69f470d7/the-weight-loss-drug-maker-reported-first-quarter-sales-of-15-17-billion-96-82-b
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works